Valeo Expects Full Enoxaparin Biosimilar Coverage By Year End
Covered For Public Reimbursement In Seven Provinces And Territories
Executive Summary
Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.